H5N1 News and Research

Latest H5N1 News and Research

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.

12 Jul 2010

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.

8 Jul 2010

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.

30 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Rare human antibodies protect mice from lethal strains of influenza

Scientists have identified a new, highly conserved molecular target on the influenza A virus and demonstrated that human antibodies against this target are protective in animal models of seasonal and highly-pathogenic avian influenza. The work was conducted by researchers at Theraclone Sciences, with collaborators at University of Wisconsin-Madison, University of Tokyo and Johns Hopkins University; and is reported this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

29 Jun 2010

Scientists discover new mechanism of H5N1 circulation and transmission in nature

A team of scientists, led by Mauro Delogu, virologist from the Veterinary Faculty of the Bologna University and researchers from the Istituto Superiore di Sanit-, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia and St. Jude Children's Research Hospital (Memphis, Tennessee) have discovered a new way of avian influenza transmission.

29 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

Mount Sinai School of Medicine has completed an exclusive option agreement with Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, for intellectual property related to RNAi applications in vaccine development. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in infectious disease.

18 Jun 2010

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.

15 Jun 2010

Investment report on Novavax

MicroStockProfit.com announces an investment report featuring Novavax Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

11 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

PuriCore sales decreases 9.9% to $10.0 million for first-quarter 2010

PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today issued its Interim Management Statement covering the period January 1, 2010, to March 31, 2010.

28 May 2010

PuriCore revenue increases 28% to $40.0 million for year ending December 31, 2009

PuriCore, the water-based clean technology company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announced its Final Results for the year ending December 31, 2009, and the availability of its 2009 annual report on its website.

28 May 2010

NanoViricides reports $2.95M in cash, $305,000 in prepaid expenses for quarter ended March 31, 2010

NanoViricides, Inc., has filed its quarterly report with the Securities and Exchange Commission on Thursday, May 20th, in a timely fashion.

24 May 2010

University of Sydney hosts emerging infectious diseases and biosecurity conference

The latest research to combat emerging infectious diseases threatening Australia is being presented at the Sydney Institute of Emerging Infectious Diseases and Biosecurity Conference at the University of Sydney today.

19 May 2010

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010.

18 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

H5N1 News and Research

Latest H5N1 News and Research

Report on program to develop, test nasally delivered H5N1 vaccine filed with Japan's MHLW

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Rare human antibodies protect mice from lethal strains of influenza

Scientists discover new mechanism of H5N1 circulation and transmission in nature

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Mount Sinai School of Medicine, Alnylam collaborate to develop microRNA-based attenuated influenza viruses

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Investment report on Novavax

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

PuriCore sales decreases 9.9% to $10.0 million for first-quarter 2010

PuriCore revenue increases 28% to $40.0 million for year ending December 31, 2009

NanoViricides reports $2.95M in cash, $305,000 in prepaid expenses for quarter ended March 31, 2010

University of Sydney hosts emerging infectious diseases and biosecurity conference

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

H5N1 News and Research

Latest H5N1 News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in